S Halazy. Designing heterocyclic selective kinase inhibitors: from concept to new drug candidates. ARKIVOC 2006 (vii) 496-508.
C Chiara Ferrandi et al. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult. Scler. J. 2011, 17(1), 43-56.
SS Bhagwat. Chapter 17 MAP Kinase Inhibitors in Inflammation and Autoimmune Disorders. Ann. Rep. Med. Chem. 2007, 42, 265-278.
の阻害剤である:
JNK, Ser/Thr Protein Kinase.
身体の状態 :
Solid
溶解度 :
Soluble in DMSO (10.8 mg/ml), and 0.1N HCl (aq.) (44.4 mg/ml). Insoluble in water.